Статья
Перикардиты. Клинические рекомендации 2022
Российское кардиологическое общество (РКО)При участии: Евразийской ассоциации терапевтов, Российского научного медицинского общества терапевтов (РНМОТ), Российского общества патологоанатомов, Российского общества рентгенологов и радиологов (РОРР)Одобрено Научно-практическим Советом Минздрава Российской Федерации (заседание от 30.09.2022 г.)
1. Adler Y, Charron P, Imazio M, et al. 2015 ESC guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2015;36:2921-64. doi:10.1093/eurheartj/ehv318.
2. He Y, Sawalha AH. Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol. 2018;30(5):490-7. doi:10.1097/BOR.0000000000000522.
3. Zipes D, Libby P, Bonow R, et al. Braunwald’s Heart Disease: A textbook of cardiovascular medicine, 2-Volume Set 11th. Philadelphia: Elsevier; 2019. ISBN-100275970922. ISBN-13 978-0323463423.
4. Galluzzo A, Imazio M. Advances in medical therapy for pericardial diseases. Expert Rev Cardiovasc Ther. 2018;16(9):635-43. doi:10.1080/14779072.2018.1510315.
5. Maisch B, Rupp H, Ristic A, Pankuweit S. Pericardioscopy and epi- and pericardial biopsy — a new window to the heart improving etiological diagnoses and permitting targeted intrapericardial therapy. Heart Fail Rev. 2013;18:317-28. doi:10.1007/s10741-013-9382-y.
6. Chiabrando JG, Bonaventura A, Vecchié A, et al. Management of acute and recurrent pericarditis: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75(1):76-92. doi:10.1016/j.jacc.2019.11.021.
7. Ismail TF. Acute pericarditis: Update on diagnosis and management. Clin Med (Lond). 2020;20(1):48-51. doi:10.7861/clinmed.cme.20.1.4.
8. Imazio M, Brucato A, Derosa FG, et al. Aetiological diagnosis in acute and recurrent pericarditis: when and how. J Cardiovasc Med (Hagerstown). 2009;10:217-30. doi:10.2459/JCM.0b013e328322f9b1.
9. Mager A, Berger D, Ofek H, et al. Prodromal symptoms predict myocardial involvement in patients with acute idiopathic pericarditis. Int J Cardiol. 2018;270:197-9. doi:10.1016/j.ijcard.2018.05.128.
10. Rey F, Delhumeau-Cartier C, Meyer P, Genne D. Is acute idiopathic pericarditis associated with recent upper respiratory tract infection or gastroenteritis? A case-control study. BMJ Open. 2015;5(11):e009141. doi:10.1136/bmjopen-2015-009141.
11. Hammer Y, Bishara J, Eisen A, et al. Seasonal patterns of acute and recurrent idiopathic pericarditis. Clin Cardiol. 2017;40:1152-5. doi:10.1002/clc.22804.
12. Noubiap JJ, Agbor VN, Ndoadoumgue AL, et al. Epidemiology of pericardial diseases in Africa: a systematic scoping review. Heart. 2019;105(3):180-8. doi:10.1136/heartjnl-2018-313922.
13. Isiguzo G, Du Bruyn E, Howlett P, Nysekhe M. Diagnosis and management of tuberculous pericarditis: What is new? Curr Cardiol Rep. 2020;22(1):2. doi:10.1007/s11886-020-1254-1.
14. Klacsmann PG, Bulkley BH, Hutchins GM. The changed spectrum of purulent pericarditis: an 86 year autopsy experience in 200 patients. Am J Med. 1977;63:666-73.
15. Skajaa N, Horváth-Puhó E, Adelborg K, et al. Lack of seasonality in occurrence of pericarditis, myocarditis, and endocarditis. Ann Epidemiol. 2019;37:77-80. doi:10.1016/j.annepidem.2019.07.005.
16. McNamara N, Ibrahim A, Satti Z, et al. Acute pericarditis: a review of current diagnostic and management guidelines. Future Cardiol. 2019;15(2):119-26. doi:10.2217/fca-2017-0102.
17. Gouriet F, Levy PY, Casalta JP, et al. Etiology of pericarditis in a prospective cohort of 1162 cases. Am J Med. 2015;128:784.e1-8. doi:10.1016/j.amjmed.2015.01.040.
18. Imazio M, Hoit BD. Post-cardiac injury syndromes. An emerging cause of pericardial diseases. Int J Cardiol. 2013;168:648-52. doi:10.1016/j.ijcard.2012.09.052.
19. Llubani R, Bohm M, Imazio M, et al. The first post-cardiac injury syndrome reported following transcatheter aortic valve implantation: a case report. Eur Heart J Case Rep. 2018;2(4):yty107. doi:10.1093/ehjcr/yty107.
20. Lehto J, Gunn J, Karjalainen P, et al. Incidence and risk factors of postpericardiotomy syndrome requiring medical attention: The Finland postpericardiotomy syndrome study. J Thorac Cardiovasc Surg. 2015;149:1324-9. doi:10.1016/j.jtcvs.2015.01.031.
21. Yukumi S, Ichiki H, Funada J, et al. Postcardiac injury syndrome following vascular interventional radiofrequency ablation for paroxysmal atrial fibrillation. Respir Med Case Rep. 2015;15:89-91. doi:10.1016/j.rmcr.2015.03.008.
22. Han J, Zhang Y, Zhou D, et al. Uncommon presentation of postcardiac injury syndrome induced by radiofrequency catheter ablation for atrial fibrillation: Only pulmonary parenchymal inflammation. J Cardiol Cases. 2016;14:17-20. doi:10.1016/j.jccase.2016.03.002.
23. Paiardi S, Cannata F, Ciccarelli M, et al. Post-cardiac injury syndrome: an atypical case following percutaneous coronary intervention. Am J Emerg Med. 2017;35(12):1985.e2. doi:10.1016/j.ajem.2017.09.005.
24. Li W, Sun J, Yu Y, et al. Clinical features of post cardiac injury syndrome following catheter ablation of arrhythmias: Systematic review and additional cases. Heart Lung Circ. 2019;28(11):1689-96. doi:10.1016/j.hlc.2018.09.001.
25. Montrief T, Davis WT, Koyfman A, Long B. Mechanical, inflammatory, and embolic complications of myocardial infarction: An emergency medicine review. Am J Emerg Med. 2019;37(6):1175-83. doi:10.1016/j.ajem.2019.04.003.
26. Lador A, Hasdai D, Mager A, et al. Incidence and prognosis of pericarditis after ST-elevation myocardial infarction (from the Acute Coronary Syndrome Israeli Survey 2000 to 2013 Registry Database). Am J Cardiol. 2018;121(6):690-4. doi:10.1016/j.amjcard.2017.12.006.
27. Chahine J, Ala CK, Gentry JL, et al. Pericardial diseases in patients with hypothyroidism. Heart. 2019;105:1027-33. doi:10.1136/heartjnl-2018-314528.
28. Ghosh AK, Crake T, Manisty C, Westwood M. Pericardial disease in cancer patients. Curr Treat Options Cardiovasc Med. 2018;20(7):60. doi:10.1007/s11936-018-0654-7.
29. Burazor I, Aviel-Ronen S, Imazio M, et al. Primary malignancies of the heart and pericardium. Clin Cardiol. 2014; 37(9):582-8. doi:10.1002/clc.22295.
30. Restrepo CS, Vargas D, Ocazionez D, et al. Primary pericardial tumors. Radiographics. 2013;33(6):1613-30. doi:10.1148/rg.336135512.
31. Szpakowski N, Desai MY. Radiation-associated pericardial disease. Curr Cardiol Rep. 2019;21(9):97. doi:10.1007/s11886-019-1192-y.
32. Imazio M, Colopi M, De Ferrari GM. Pericardial diseases in patients with cancer: contemporary prevalence, management and outcomes. Heart. 2020;106(8):569-574. doi:10.1136/heartjnl-2019-315852.
33. Ala CK, Klein AL, Moslehi JJ. Cancer treatment-associated pericardial disease: epidemiology, clinical presentation, diagnosis, and management. Curr Cardiol Rep. 2019;21(12):156. doi:10.1007/s11886-019-1225-6.
34. Altan M, Toki MI, Gettinger SN, et al. Immune checkpoint inhibitor-associated pericarditis. J Thorac Oncol 2019;14:1102-8. doi:10.1016/j.jtho.2019.02.026.
35. Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579-89. doi:10.1016/S1470-2045(18)30608-9.
36. De Almeida DVP, Gomes JR, Haddad FJ, Buzaid AC. Immune mediated pericarditis with pericardial tamponade during nivolumab therapy. J Immunother. 2018;41(7):329-31. doi:10.1097/CJI.0000000000000217.
37. Yun S, Vincelette ND, Mansour I, et al. Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med. 2015;2015:794842. doi:10.1155/2015/794842.
38. Nesfeder J, Elsensohn AN, Thind M, et al. Pericardial effusion with tamponade physiology induced by nivolumab. Int J Cardiol. 2016;222:613-4. doi:10.1016/j.ijcard.2016.08.023.
39. Kushnir I, Wolf I. Nivolumab-induced pericardial tamponade: a case report and discussion. Cardiology. 2017;136(1):49-51. doi:10.1159/000447053.
40. Hu JR, Florido R, Lipson EJ, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854-68. doi:10.1093/cvr/cvz026.
41. Imazio M, Demichelis B, Cecchi E, et al. Cardiac troponin I in acute pericarditis. J Am Coll Cardiol. 2003;42:2144-8. doi:10.1016/j.jacc.2003.02.001.
42. Bonnefoy E, Godon P, Kirkorian G, et al. Serum cardiac troponin I and ST-segment elevation in patients with acute pericarditis. Eur Heart J. 2000;21:832-6. doi:10.1053/euhj.1999.1907.
43. Imazio M, Trinchero R. Myopericarditis: etiology, management, and prognosis. Int J Cardiol. 2008;127:17-26. doi:10.1016/j.ijcard.2007.10.053.
44. Скрипка А. И., Бучнева А. В., Ванхин В. В. и др. Клиническое наблюдение: туберкулезный миоперикардит в практике врача кардиолога. Рациональная Фармакотерапия в Кардиологии. 2018;14(5):691-8. doi:10.20996/1819-6446-2018-14-5-691-698.
45. Saricam E, Saglam Y, Hazirolan T. Clinical evaluation of myocardial involvement in acute myopericarditis in young adults. BMC Cardiovasc Disord. 2017;17(1):129. doi:10.1186/s12872-017-0564-8.
46. Søgaard KK, Farkas DK, Ehrenstein V, et al. Pericarditis as a marker of occult cancer and a prognostic factor for cancer mortality. Circulation. 2017;136(11):996-1006. doi:10.1161/circulationaha.116.024041.
47. Søgaard KK, Sørensen HT, Smeeth L, Bhaskaran K. Acute pericarditis and cancer risk: A matched cohort study using linked UK primary and secondary care data. J Am Heart Assoc. 2018;7(16):e009428. doi:10.1161/JAHA.118.009428.
48. Imazio M, Gaita F. Diagnosis and treatment of pericarditis. Heart. 2015;101(14):1159-68. doi:10.1136/heartjnl-2014-306362.
49. Brucato A, Imazio M, Cremer PC, et al. Recurrent pericarditis: still idiopathic? The pros and cons of a well-honoured term. Intern Emerg Med. 2018;13:839-44. doi:10.1007/s11739-018-1907-x.
50. Abu Fanne R, Banai S, Chorin U, et al. Diagnostic yield of extensive infectious panel testing in acute pericarditis. Cardiology. 2011;119:134-9. doi:10.1159/000330928.
51. Fallek Boldes O, Dahan S, Segal Y, et al. Characteristics of pericardial biopsy: 100 cases in a single center. Isr Med Assoc J. 2019;21(3):183-8.
52. Young PM, Glockner JF, Williamson EE, et al. MR imaging findings in 76 consecutive surgically proven cases of pericardial disease with CT and pathologic correlation. Int J Cardiovasc Imaging. 2012;28:1099-109.
53. Mutyaba AK, Balkaran S, Cloete R, et al. Constrictive pericarditis requiring pericardiectomy at Groote Schuur Hospital, Cape Town, South Africa: causes and perioperative outcomes in the HIV era (1990–2012). J Thorac Cardiovasc Surg. 2014;148:3058-65.
54. Imazio M, Brucato A, Maestroni S, et al. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124:1270-5.
55. Zmora I, Wiener-Well Y, Alpert EA. A case of purulent pneumococcal pericarditis. American Journal of Emergency Medicine. 2019;37(5):1006.e5-1006.e7. doi:10.1016/j.ajem.2019.02.013.
56. Ganji M, Ruiz J, Kogler W, et al. Methicillin-resistant Staphylococcus aureus pericarditis causing cardiac tamponade. IDCases. 2019;18:e00613. doi:10.1016/j.idcr.2019.e00613.
57. Vijay A, Stendahl JC, Rosenfeld LE. Mycoplasma Pneumoniae Pericarditis. Am J Cardiol. 2019;123(8):1383-1384. doi:10.1016/j.amjcard.2019.01.014.
58. Kiyasu Y, Akiyama D, Kurihara Y, et al. Pericarditis caused by Campylobacter fetus subspecies fetus associated with ingestion of raw beef liver. J Infect Chemother. 2017;23:833-6.
59. Shinha T, Fujita H. Pericarditis due to Neisseria meningitidis serogroup W135. IDCases. 2018;12:53-5.
60. Tuck BC, Townsley MM. Clinical update in pericardial diseases. J Cardiothorac Vasc Anesth. 2019;33(1):184-99. doi:10.1053/j.jvca.2018.04.003.
61. Schwier NC, Cornelio CK, Epperson TM. Managing acute and recurrent idiopathic pericarditis. JAAPA. 2020;33(1):16-22. doi:10.1097/01.JAA.0000615468.46936.6d.
62. Imazio M, Gaita F. Acute and recurrent pericarditis. Cardiol Clin. 2017;35(4):505-13. doi:10.1016/j.ccl.2017.07.004.
63. Brady WJ, Perron AD, Martin ML, et al. Cause of ST segment abnormality in ED chest pain patients. Am J Emerg Med. 2001;19(1):25-8.
64. Kytö V, Sipilä J, Rautava P. Clinical profile and influences on outcomes in patients hospitalized for acute pericarditis. Circulation. 2014;130:1601-6. doi:10.1161/CIRCULATIONAHA.114.010376.
65. Sagrista-Sauleda J, Barrabes JA, Permanyer-Miralda G, Soler-Soler J. Purulent pericarditis: review of a 20-year experience in a general hospital. J Am Coll Cardiol. 1993;22:1661-5.
66. Obihara NJ, Walters E, Lawrenson J, et al. Tuberculous pericardial effusions in children. J Pediatric Infect Dis Soc. 2018;7(4):346-9. doi:10.1093/jpids/pix087.
67. Imazio M, Gribaudo E, Gaita F. Recurrent pericarditis. Prog Cardiovasc Dis. 2017;59:360-8. doi:10.1016/j.pcad.2016.10.001.
68. Mody P, Bikdeli B, Wang Y, et al. Trends in acute pericarditis hospitalizations and outcomes among the elderly in the United States, 1999-2012. Eur Heart J Qual Care Clin Outcomes. 2018;4(2):98-105.
69. Rees MJ, Wilson A. Purulent pneumococcal pericarditis, a vaccine-preventable illness. Oxf Med Case Reports. 2019;2019(8):omz078. doi:10.1093/omcr/omz078.
70. Agbor VN, Essouma M, Ntusi NAB, et al. Heart failure in sub-Saharan Africa: a contemporaneous systematic review and meta-analysis. Int J Cardiol. 2018;257:207-15. doi:10.1016/j.ijcard.2017.12.048.
71. Kumar N, Pandey A, Jain P, Garg N. Acute pericarditis-associated hospitalization in the USA: a nationwide analysis, 2003-2012. Cardiology. 2016;135(1):27-35.
72. Xie D, Cheng B, Sheng Y, Jin J. Diagnostic accuracy of adenosine deaminase for tuberculous pericarditis: a meta-analysis. Eur Rev Med Pharmacol Sci. 2015;19(22): 4411-8.
73. Zhong F, Dai T, Sheng Y. Correlation study between ADA and IFN-γ gene polymorphisms and the risk of developing tuberculous pericarditis. Gene. 2018;676:214-8.
74. Gerardin C, Mageau A, Benali K, et al. Increased FDG-PET/CT pericardial uptake identifies acute pericarditis patients at high risk for relapse. International Journal of Cardiology. 2018;271:192-4.
75. Pasipanodya JG, Mubanga M, Ntsekhe M, et al. Tuberculous Pericarditis is Multibacillary and Bacterial Burden Drives High Mortality. EBioMedicine. 2015;2:1634-9.
76. Farzad A, Schussler JM. Acute Myopericardial Syndromes. Cardiol Clin. 2018;36(1):103-14. doi:10.1016/j.ccl.2017.09.004.
77. Imazio M, Cooper LT. Management of myopericarditis. Expert Rev Cardiovasc Ther. 2013 Feb;11(2):193-201. doi:10.1586/erc.12.184.
78. Hussain R, Halmai L, Subkovas E. Unexpected sudden death in a young man with myopericarditis — a case report. J Ayub Med Coll Abbottabad. 2015;27(1):239-40.
79. Ren Y, Qiu J, Li Z, Li C. P-wave terminal force in lead V1 is a predictive indicator for the diagnosis of tuberculous constrictive pericarditis. Heart & Lung. 2019;48:155-8.
80. Gentry J, Klein AL, Gellis CL.Transient Constrictive Pericarditis: Current Diagnostic and Therapeutic Strategies. Curr Cardiol Rep. 2016;18(5):41.
81. Miranda WR, Oh JK. Effusive-constrictive pericarditis. Cardiol Clin. 2017;35:551-8.
82. Ntsekhe M, Wiysonge CS, Commerford PJ, Mayosi BM. The prevalence and outcome of effusive constrictive pericarditis: a systematic review of the literature Cardiovasc. J. Afr. 2012;23:281-5.
83. Imazio M, Lazaros G, Brucato A, Gaita F. Recurrent pericarditis: new and emerging therapeutic options. Nature Reviews Cardiology. 2015;13(2):99-105.
84. Imazio M, Adler Y. Management of pericardial effusion. Eur Heart J. 2013;34:1186-97.
85. Vakamudi S, Ho N, Cremer PC. Pericardial Effusions: Causes, Diagnosis, and Management. Prog Cardiovasc Dis. 2017;59(4):380-8. doi:10.1016/j.pcad.2016.12.009.
86. Ristić AD, Imazio M, Adler Y, et al. Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardialand Pericardial Diseases. Eur Heart J. 2014;35:2279-84.
87. Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis. J Cardiovasc Med (Hagerstown). 2010;11:712-22.
88. Goldstein JA. Cardiac tamponade in the interventional era: A paradigm shift in etiology and outcomes. Catheter Cardiovasc Interv. 2020;95(3):387-8. doi:10.1002/ccd.28764.
89. Herzog E, ed. Management of Pericardial Disease. Springer International Publishing Switzerland. 2014, p. 182.
90. Montera MW, Mesquita ET, Colafranceschi AS, et al. I Brazillan Guidelines on Myocarditis and Pericarditis Arq. Bras. Cardiol. 2013;100 (4 Suppl. 1):1-36.
91. Chang SA. Tuberculous and infectious pericarditis. Cardiol Clin. 2017;35:615-22.
92. Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. Circulation. 2010;121:916-28.
93. Leitman M, Bachner-Hinenzon N, Adam D, et al. Speckle tracking imaging in acute inflammatory pericardial diseases. Echocardiography. 2011;28:548-55.
94. Raatikka M, Pelkonen PM, Karjalainen J, Jokinen EV. Recurrent pericarditis in children and adolescents: report of 15 cases. J Am Coll Cardiol. 2003;42(4):759-64.
95. Мячикова В. Ю., Титов В. А., Маслянский А. Л., Моисеева О. М. Идиопатический рецидивирующий перикардит — смена парадигмы? Российский кардиологический журнал. 2019;(11):155-63. doi:10.15829/1560-4071-2019-11-155-163.
96. Wiysonge CS, Ntsekhe M, Thabane L, et al. Interventions for treating tuberculous pericarditis (Review). Cochrane Database Syst Rev. 2017;9(9):CD000526. doi:10.1002/14651858.CD000526.pub2.
97. Lazaros G, Antonopoulos AS, Imazio M, et al. Clinical significance of pleural effusions and association with outcome in patients hospitalized with a first episode of acute pericarditis. Internal and Emergency Medicine. (2019)14:745-51.
98. Cosyns B, Garbi M, Separovic J, et al. Update of the echocardiography core syllabus of the European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc Imaging. 2013;14(9):837-9. doi:10.1093/ehjci/jet140.
99. Alharthi MS, Jiamsripong P, Calleja A, et al. Selective echocardiographic analysis of epicardial and endocardial left ventricular rotational mechanics in an animal model of pericardial adhesions. Eur J Echocardiogr. 2009;10:357-62.
100. Oh JK, Hatle LK, Seward JB, et al. Diagnostic role of Doppler echocardiography in constrictive pericarditis. Journal of the American College of Cardiology. 1994;23: 154-62.
101. Reuss CS, Wilansky SM, Lester SJ, et al. Using mitral “annulus reversus” to diagnose constrictive pericarditis. European Journal of Echocardiography. 2009;10:372-5.
102. Welch TD, Ling LH, Espinosa RE, et al. Echocardiographic diagnosis of constrictive pericarditis Mayo Clinic criteria. Circulation: Cardiovascular Imaging. 2014;7:526-34.
103. Kusunose K, Dahiya A, Popović ZB, et al. Biventricular mechanics in constrictive pericarditis comparison with restrictive cardiomyopathy and impact of pericardiectomy. Circulation: Cardiovascular Imaging. 2013;6:399-406.
104. Sengupta PP, Mohan JC, Mehta V, et al. Doppler tissue imaging improves assessment of abnormal interventricular septal and posterior wall motion in constrictive pericarditis J. Am. Soc. Echocardiogr. 2005;18:226-30.
105. Veress G, Ling LH, Kim KH, et al. Mitral and tricuspid annular velocities before and after pericardiectomy in patients with constrictive pericarditis. Circ. Cardiovasc. Imaging. 2011;4:399-407.
106. Dal-Bianco JP, Sengupta PP, Mookadam F, et al. Role of echocardiography in the diagnosis of constrictive pericarditis J. Am. Soc. Echocardiogr. 2009;22(1):24-33.
107. Sohn DW, Kim YJ, Kim HS, et al. Unique features of early diastolic mitral annulus velocity in constrictive pericarditis J. Am. Soc. Echocardiogr. 2004;17:222-6.
108. Sengupta PP, Mohan JC, Mehta V, et al. Accuracy and pitfalls of early diastolic motion of the mitral annulus for diagnosing constrictive pericarditis by tissue Doppler imaging. Am. J. Cardiol. 2004;93:886-90.
109. Ha JW, Ommen SR, Tajik AJ, et al. Differentiation of constrictive pericarditis from restrictive cardiomyopathy using mitral annular velocity by tissue Doppler echocardiography. Am. J. Cardiol. 2004;94:316-9.
110. Choi EY, Ha JW, Kim JM, et al. Incremental value of combining systolic mitral annular velocity and time difference between mitral inflow and diastolic mitral annular velocity to early diastolic annular velocity for differentiating constrictive pericarditis from restrictive cardiomyopathy. J. Am. Soc. Echocardiogr. 2007;20:738-43.
111. Veress G, Feng D, Oh JK. Echocardiography in pericardial diseases: new developments. Heart Fail Rev. 2013;8(3):267-75.
112. Oh JK, Tajik AJ, Appleton CP, et al. Preload reduction to unmask the characteristic Doppler features of constrictive pericarditis. A new observation. Circulation. 1997;95:796-9.
113. Wann LS, Weyman AE, Dillon JC, Feigenbaum H. Premature pulmonary valve opening. Circulation. 1977;55:128-33.
114. Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography Clinical Recommendations for Multimodality Cardiovascular Imaging of Patients with Pericardial Disease. J. Am. Soc. Echocardiogr. 2013;26:965-1012.
115. Alajaji W, Xu B, Sripariwuth A, et al. Noninvasive Multimodality Imaging for the Diagnosis of constrictive pericarditis. Circ Cardiovasc Imaging. 2018;11(11):e007878.
116. Welch T, Ling L, Anavekar N, et al. Modern Echocardiographic Diagnosis of Constrictive Pericarditis. J Am Coll Cardiol. 2013;61(10):e1278.
117. von Bibra H, Schober K, Jenni R, et al. Diagnosis of constrictive pericarditis by pulsed Doppler echocardiography of the hepatic vein. Am. J. Cardiol. 1989;63:483-8.
118. Imazio M, Cecchi E, Demichelis B, et al. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115:2739-44.
119. Lilly LS. Treatment of acute and recurrent idiopathic pericarditis. Circulation. 2013;127:1723-6.
120. Imazio M, Brucato A, Mayosi BM, et al. Medical therapy of pericardial diseases: part II: noninfectious pericarditis, pericardial effusion and constrictive pericarditis. J Cardiovasc Med (Hagerstown). 2010;11:785-94.
121. Rehman KA, Betancor J, Xu B, et al. Uremic pericarditis, pericardial effusion, and constrictive pericarditis in end-stage renal disease: insights and pathophysiology. Clinical Cardiology. 2017;40:839-46.
122. Appleton CP, Hatle LK, Popp RL. Cardiac tamponade and pericardial effusion: respiratory variation in transvalvular flow velocities studied by Doppler echocardiography. Journal of the American College of Cardiology. 1988;116:1020-30.
123. Kim KH, Miranda WR, Sinak LJ, et al. Effusive-constrictive pericarditis after pericardiocentesis: incidence, associated findings, and natural history. JACC Cardiovascular Imaging. 2018;11:534-41.
124. Ling LH, Oh JK, Breen JF, et al. Calcific constrictive pericarditis: is it still with us? Ann Intern Med. 2000;132:444-50.
125. Cremer PC, Kumar A, Kontzias A, et al. Complicated pericarditis understanding risk factors and pathophysiology to inform imaging and treatment. Journal of the American College of Cardiology. 2016;68:2311-28.
126. Bogaert J, Francone M. Cardiovascular magnetic resonance in pericardial diseases. J Cardiovasc Magn Reson. 2009;11:14.
127. Misselt AJ, Harris SR, Glockner J, et al. MR imaging of the pericardium. Magn Reson Imaging Clin N Am. 2008;16:185-99.
128. Alter P, Figiel JH, Rupp TP, et al. MR, CT, and PET imaging in pericardial disease. Heart Fail Rev. 2013;18:289-306.
129. Cosyns B, Plein S, Nihoyanopoulos P, et al. European Association of Cardiovascular Imaging (EACVI) position paper: multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging. 2015;16(1):12-31. doi:10.1093/ehjci/jeu128.
130. Imazio M. Contemporary management of pericardial diseases. Curr Opin Cardiol. 2012;27:308-17.
131. Bogaert J, Francone M. Pericardial disease: value of CT and MR imaging. Radiology. 2013;267:340-56.
132. Harrison’s Principles of Internal Medicine: Volumes 1 and 2, 18th Edition. Edited by Longo D. L., Kasper D. L. et al. 2019.
133. Rajiah P, Kanne JP. Computed tomography of the pericardium and pericardial disease. J. Cardiovasc. Comput. Tomogr. 2010;4:3-18.
134. Talreja DR, Edwards WD, Danielson GK, et al. Constrictive pericarditis in 26 patients with histologically normal pericardial thickness. Circulation. 2003;108:1852-7.
135. Манафов С. С., Аббасов Ф. Э., Гейбатов И. Д. Компьютерная томография в диагностике перикардитов в различных фазах его развития. Медицинская визуализация. 2009;6:53-7.
136. Lachhab A, Doghmi N, Zouhairi A, et al. Use magnetic resonance imaging in assessment of constrictive pericarditis: a Moroccan center experience. Int Arch Med. 2011;4(1):36.
137. Ariyarajah V, Jassal DS, Kirkpatrick I, Kwong RY. The utility of cardiovascular magnetic resonance in constrictive pericardial disease. Cardiol Rev. 2009;17(2):77-82.
138. Taylor AM, Dymarkowski S, Verbeken EK, Bogaert J. Detection of pericardial inflammation with late-enhancement cardiac magnetic resonance imaging: initial results. Eur. Radiol. 2006;16:569-74.
139. Welch TD. Constrictive pericarditis: Diagnosis, management and clinical outcomes. Heart. 2018;104:725-31.
140. Imazio M, Brucato A, Cemin R, et al. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann Intern Med. 2011;155:409-14.
141. Imazio M, Belli R, Brucato A, et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomized trial. Lancet. 2014;383:2232-7.
142. Smilde BJ, Woudstra L, Fong Hing G, et al. Colchicine aggravates coxsackievirus B3 infection in mice. Int J Cardiol. 2016;216:58-65.
143. Maestroni S, Imazio M, Valenti A, et al. Is colchicine really harmful in viral myocarditis? Int J Cardiol. 2017;229:42.
144. Mauro A, Mezzaroma E, Torrado J, et al. A novel Nlrp3 inflammasome inhibitor prevents acute pericarditis in an experimental mouse model. Circulation. 2016;134 Suppl 1:A15152.
145. Choi DH, Choi JS, Li C, Choi JS. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin. Pharmacol Rep. 2011;63:1574-82.
146. Imazio M, Bobbio M, Cecchi E, et al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112:2012-6.
147. Imazio M, Demichelis B, Parrini I, et al. Dayhospital treatment of acute pericarditis: a management program for outpatient therapy. J Am Coll Cardiol. 2004;43:1042-6.
148. Schwier N, Tran N. Non-Steroidal Anti-Inflammatory Drugs and Aspirin Therapy for the Treatment of Acute and Recurrent Idiopathic Pericarditis.Pharmaceuticals (Basel). 2016;9(2). pii: E17.
149. Leung YY. Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341-50.
150. Xu B, Harb SC, Cremer PC. New insights into pericarditis: mechanisms of injury and therapeutic targets. Current cardiology reports. 2017;19(7):60.
151. Imazio M, Brucato A, Cumetti D, et al. Corticosteroids for Recurrent pericaditis: High versus Low doses: A nonrandomized observation. Circulation. 2008;118(6):667-71.
152. Vianello F, Cinetto F, Cavraro M, et al. Azathioprine in isolated recurrent pericarditis: a singlecentre experience. Int J Cardiol. 2011;147:477-8.
153. Imazio M, Lazaros G, Picardi E, et al. Intravenous human immunoglobulins for refractory recurrent pericarditis. Journal of Cardiovascular Medicine. 2016;17(4):263-9.
154. Moll M, Kuemmerle-Deschner JB. Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clinical Immunology. 2013;147(3):242-75.
155. Imazio M, Andreis A, De Ferrari GM, et al. Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. Eur J Prev Cardiol. 2020;27(9):956-964. doi:10.1177/2047487319879534.
156. Imazio M, Brucato A, Trinchero R, et al. Colchicine for pericarditis: hype or hope? Eur Heart J. 2009;30:532-9.
157. Berg J, Lovrinovic M, Baltensperger N, et al. Non-steroidal anti-inflammatory drug use in acute myopericarditis: 12-month clinical follow-up. Open Heart. 2019;6(1):e000990. doi:10.1136/openhrt-2018-000990.
158. Imazio M, Trinchero R. The spectrum of inflammatory myopericardial diseases. Int J Cardiol . 2010;144(1):134. doi:10.1016/j.ijcard.2008.12.118.
159. Seidenberg PH, Haynes J. Pericarditis: diagnosis, management, and return to play. Curr Sports Med Rep. 2006;5:74-9.
160. Liebenberg J, van der Bijl P. A “vanishing”, tuberculous, pericardial effusion. Korean Circ J. 2016;46(6):879-81.
161. Wiyeh AB, Ochodo EA, Wiysonge CS, et al. A systematic review of the efficacy and safety of intrapericardial fibrinolysis in patients with pericardial effusion. Int J Cardiol. 2018;250:223-8.
162. Doctor NS, Shah AB, Coplan N, Kronzon I. Acute Pericarditis. Prog Cardiovasc Dis. 2017;59(4):349-359. doi:10.1016/j.pcad.2016.12.001.
163. Mayosi BM, Ntsekhe M, Bosch J, et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N. Engl. J. Med. 2014;371:1121-30.
164. Maisch B. Management of pericarditis and pericardial effusion, constrictive and effusive-constrictive pericarditis. Herz. 2018;43(7):663-78.
165. Косоногов А. Я., Немирова С. В., Поздышев В. И. и др. Жизнеугрожающие состояния при перикардитах различной этиологии: диагностика и лечение. Медицинский альмонах. 2019;2(59):40-5.
166. Colak A, Becit N, Kaya U, et al. Treatment of Pericardial Effusion Through Subxiphoid Tube Pericardiostomy and Computerized Tomography- or Echocardiography — Guided Percutaneous Catheter Drainage Methods. Braz J Cardiovasc Surg. 2019;34(2):194-202.
167. Гульмурадов Т.Г., Дадабаев Д. У., Рашидов Ф.Ш., Джаббаров А. А. Видеоторакоскопическое лечение хронического экссудативного перикардита. Вестник последипломного образования в сфере здравоохранения. 2019;1:9-15.
168. Gillaspie EA, Stulak JM, Daly RC, et al. A 20-year experience with isolated pericardiectomy: Analysis of indications and outcomes. J Thorac Cardiovasc Surg. 2016;152:448-58.
169. Титов К. С., Киселевский М. В. Современная тактика лечения опухолевых перикардитов. Злокачественные опухоли. 2017;(3):57-61.
170. Petcu СP, Droc I. The Efficiency of Surgical Subxiphoid Pericardial Drainage and Percutaneous Pericardial Drainage in Pericardial Effusions Associated with Cardiac Tamponade Chirurgia (Bucur). 2013;108(2):226-33.
171. Langdon SE, Seery K, Kulik A. Contemporary outcomes after pericardial window surgery: impact of operative technique. J Cardiothorac Surg. 2016;11(1):73.
172. Volk L, Lee LY, Lemaire A. Surgical pericardial drainage procedures have a limited diagnostic sensitivity J Card Surg. 2019;34(12):1573-6.
173. Хирургические инфекции груди и живота: руководство для врачей. Под ред. проф. Б. Н. Котива и проф. Л. Н. Бисенкова. Санкт-Петербург: СпецЛит, 2016. 671 с.
174. Воскресенский О. В., Тарабрин Е. А., Белозеров Г. Е. и др. Лечение хронической тампонады сердца при его новообразованиях. Неотложная медицинская помощь. Журнал им. Н. В. Склифосовского. 2019;8(1):81-6.
175. Писклова Ю. В., Бучнева О. В. Опыт лечения экссудативных перикардитов с использованием миниинвазивных доступов. International Scientific and Practical Conference World science. 2018;3-1(29):39-41 (торакоскопия).
176. Благова О. В., Алиева И. Н., Недоступ А. В. и др. Экссудативно-констриктивный туберкулезный перикардит в сочетании с артритом в практике кардиолога: торакоскопическая биопсия как путь к диагнозу и лечению. Терапевтичексий архив. 2018;90(9):81-7. doi:10.26442/terarkh201890981-87.
177. Chowdhury UK, Subramaniam GK, Kumar AS, et al. Pericardiectomy for constrictive pericarditis: a clinical, echocardiographic, and hemodynamic evaluation of two surgical techniques Ann. Thorac. Surg. 2006;81:522-9.
178. Cho YH, Schaff HV, Dearani JA, et al. Completion pericardiectomy for recurrent constrictive pericarditis: importance of timing of recurrence on late clinical outcome of operation. Ann. Thorac. Surg. 2012;93:1236-41.
179. Murashita T, Schaff HV, Daly RC, et al. Experience with Pericardiectomy for Constrictive Pericarditis Over Eight Decades. Ann. Thorac. Surg. 2017;104(3):742-50.
180. Nozohoor S, Johansson M, Koul B, Cunha-Goncalves D. Radical pericardiectomy for chronic constrictive pericarditis. J Card Surg. 2018;33(6):301-7.
181. Wang FF, Hsu J, Jia FW, et al. Left ventricular strain is associated with acute postoperative refractory hypotension in patients with constrictive pericarditis and preserved ejection fraction. J Thorac Dis. 2018;10(7):4147-55.
182. Gatti G, Fiore A, Ternacle J, et al. Pericardiectomy for constrictive pericarditis: a risk factor analysis for early and late failure. Heart Vessels. 2020;35(1):92-103.
183. Choi MS, Jeong DS, Oh JK, et al. Long-term results of radical pericardiectomy for constrictive pericarditis in Korean population. J Cardiothorac Surg. 2019;14(1):32.
184. Vistarini N, Chen C, Mazine A, et al. Pericardiectomy for constrictive pericarditis: 20 years of experience at the Montreal Heart Institute. Ann Thorac Surg. 2015;100:107-13.
185. Nugue O, Millaire A, Porte H, et al. Pericardioscopy in the etiologic diagnosis of pericardial effusion in 141 consecutive patients. Circulation. 1996;94(7):1635-41.
186. Айвазьян С. А., Медведев А. П., Косоногов А. Я., Сидоров М. А. Опыт применения перикардиоскопии для диагностики и лечения заболеваний перикарда. Медицинский альманах. 2011;6(19):236-7.
187. Strobbe A, Adriaenssens T, Bennett J, et al. Etiology and long term outcome of patients undergoing pericardiocentesis. J Am Heart Assoc. 2017;6(12):e007598. doi:10.1161/JAHA.117.007598.
188. Romero J, Cerrud-Rodriguez RC, Di Biase L, et al. Combined Endocardial-Epicardial Versus Endocardial Catheter Ablation Alone for Ventricular Tachycardia in Structural Heart Disease: A Systematic Review and Meta-Analysis. JACC Clin Electrophysiol. 2019;5(1):13-24.
189. Little WC, Freeman GL. Pericardial disease. Circulation. 2006;113:1622-32.
190. Imazio M, Brucato A, Spodick DH, Adler Y. Prognosis of myopericarditis as determined from previously published reports. J Cardiovasc Med (Hagerstown). 2014;15(12):835-9. doi:10.2459/JCM.0000000000000082.
191. Keskin K, Çetinkal G, Yıldız SS, et al. Clinical characteristics and intermediate-term outcomes of young patients with uncomplicated myopericarditis. Turk Kardiyol Dern Ars. 2019;47(7):581-6. doi:10.5543/tkda.2019.63306.
192. Imazio M, Brucato A. Ferrazz P, et al. Postpericardiotomy syndrome: a proposal for diagnostic criteria. J Cardiovasc Med. 2013;14:351-3.
193. Figueras J, Barrabes JA, Serra V, et al. Hospital outcome of moderate to severe pericardial effusion complicating ST-elevation acute myocardial infarction. Circulation. 2010;122:1902-9.
194. Imazio M, Negro A, Belli R, et al. Frequency and prognostic significance of pericaditis follow-ing acute myocardial infarction treated by primary percutaneous coronary intervention. Am J Cardiol. 2009;103:1525-9.
195. Meurin P, Weber H, Renaud N, et al. Evolution of the postoperative pericardial effusion after day 15: the problem of the late tamponade. Chest. 2004;125:2182-7.
196. Meurin P, Tabet JY, Thabut G, et al. Nonsteroidal anti-inflammatory drug treatment for postoperative pericardial effusion: a multicenter randomized, double-blind tria. Ann Intern Med. 2010;152:137-42.
197. Tsang TS, Enruquez-Sarano M, Freeman WK, et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc. 2002;77:429-36.
198. Косоногов К. А., Майорова М. В., Кацубо Е. М., Косоногов А. Я. Ретроспективный анализ 5-летнего опыта хирургического лечения неинфекционных осложнений кардиостимуляции. Медицинский альманах. 2018;1(52):84-8.
199. van Osch D, Nathoe HM, Jacob KA, et al. Determinants of the postpericardiotomy syndrome: a systematic review. Eur J Clin Invest. 2017;47(6):456-67. doi:10.1111/eci.12764.
200. van Osch D, Dieleman JM, Bunge JJ, et al. Risk factors and prognosis of postpericardiotomy syndrome in patients undergoing valve surgery. J Thorac Cardiovasc Surg. 2017;153(4):878-85.e1. doi:10.1016/j.jtcvs.2016.10.075.
201. Gabaldo K, Sutlić Ž, Mišković D, et al. Postpericardiotomy syndrome incidence, diagnostic and treatment strategies: experience AT two collaborative centers. Acta Clin Croat. 2019;58(1):57-62. doi:10.20471/acc.2019.58.01.08.
202. Lehto J, Kiviniemi T, Gunn J, et al. Occurrence of Postpericardiotomy Syndrome: Association With Operation Type and Postoperative Mortality After Open-Heart Operations. J Am Heart Assoc. 2018;7(22):e010269. doi:10.1161/JAHA.118.010269.
203. Wamboldt R, Bisleri G, Glover B, et al. Primary prevention of post-pericardiotomy syndrome using corticosteroids: a systematic review. Expert Rev Cardiovasc Ther. 2018;16(6):405-12. doi:10.1080/14779072.2018.1475231.
204. Yuan SM. Postpericardiotomy Syndrome after Cardiac Operations. J Coll Physicians Surg Pak. 2020;30(1):62-6. doi:10.29271/jcpsp.2020.01.62.
205. Lutschinger LL, Rigopoulos AG, Schlattmann P, et al. Meta-analysis for the value of colchicine for the therapy of pericarditis and of postpericardiotomy syndrome [published correction appears in BMC Cardiovasc Disord. BMC Cardiovasc Disord. 2019;19(1):207. doi:10.1186/s12872-019-1190-4.
206. Lee TH, Quellet JF, Cook M, et al. Pericardiocentesis in trauma: a systematic reviews. J Trauma Acute Care Surg. 2013;75:543-9.
207. ATLS Subcommittee, American College of Surgeons Committee on Trauma. International ATLS Working Group. Advanced trauma life support (ATLS): the ninth edition. J Trauma Acute Care Surg. 2013;74:1363-6.
208. Meurin P, Lelay-Kubas S, Pierre B, et al. Colchicine for postoperative pericardial effusion: a multicentre, double-blind, randomized controlled trial. Heart. 2015;101(21):1711-6. doi:10.1136/heartjnl-2015-307827.
209. Kougkas N, Fanouriakis A, Papalopoulos I, et al. Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up. Rheumatology (Oxford). 2018;57(8):1494-1495. doi:10.1093/rheumatology/key077.
210. García-García G, Fernández-Auzmendi V, Olgado-Ferrero F, et al. Acute Miopericarditis as the Presenting Feature of Adult-Onset Still’s Disease. Reumatología Clínica. 2012;8(1),31-3.
211. Lachmann HJ, Papa R, Gerhold K, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2014;73(12):2160-7.
212. Cantarini L, Lopalco G, Selmi C, et al. Autoimmunity and autoinflammation as the yin and yang of idiopathic recurrent acute pericarditis. Autoimmunity reviews. 2015;14(2):90-7.
213. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19(3):424-30.
214. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008;22(5):773-92.
215. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nature reviews. Rheumatology. 2018;14(10):603-18.
216. Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14(5):301-16. doi:10.1038/nrendo.2018.18.
217. Leonardi A, Penta L, Cofini M, et al. Pericardial Effusion as a Presenting Symptom of Hashimoto Thyroiditis: A Case Report. Int J Environ Res Public Health. 2017;14(12). doi:10.3390/ijerph14121576.
218. Papakonstantinou PE, Gourniezakis N, Skiadas C, et al. Massive pericardial effusion without cardiac tamponade due to subclinical hypothyroidism (Hashimoto’s disease). Rural and Remote Health. 2018;18:4384. doi:10.22605/RRH4384.
219. Снитко В. Н., Виноградова Т. А., Дедуль В. И., Карева Л. В. Изолированный гидроперикард — следствие поздней диагностики первичного гипотиреоза. Журнал Гродненского государственного медицинского университета. 2017;15(5):578-80. doi:10.25298/2221-8785-2017-15-5-578-580.
220. Agarwal A, Chowdhury N, Mathur A, et al. Pericardial Effusion with Cardiac Tamponade as a form of presentation of Primary Hypothyroidism. J Assoc Physicians India. 2016;64(12):98-100.
221. Schmitt W, Roque D, Germano A. Massive pericardial effusion caused by hypothyroidism. Clin Case Rep. 2018;6(4):766-7. doi:10.1002/ccr3.1447.
222. Pasquali R, Casanueva F, Haluzik M, et al. European Society of Endocrinology Clinical Practice Guideline: Endocrine work-up in obesity. Eur J Endocrinol. 2020;182(1):G1-G32. doi:10.1530/EJE-19-0893.
223. Floriani C, Gencer B, Collet TH, Rodondi N. Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. European Heart Journal. 2018;39:503-7.
224. Ning Y, Cheng YJ, Liu LJ, et al. What is the association of cardiovascular events and mortality? A meta-analysis of 55 cohort studies involving 1,898,314 participants. BMC Medicine. 2017;15:21. doi:10.1186/s12916-017-0777-9.
225. Jonklaas J, Bianco AC, Bauer AJ, et al.; American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on thyroid hormone replacement. Thyroid. 2014;24:1670-751. doi:10.1089/thy.2014.0028.
226. Schwier NC, O’Neal K. Pharmacotherapeutic Management Strategies for Thyroid Disease-Induced Pericarditis. Annals of Pharmacotherapy, 2019;1-10. doi:10.1177/1060028019889065.
227. Schwier NC. Pharmacotherapeutic considerations for using colchicine to treat idiopathic pericarditis in the USA. Am J Cardiovasc Drugs. 2015;15:295-306.
228. Bui PV, Zaveri SN, Pierce JR Jr. Sanguineous Pericardial Effusion and Cardiac Tamponade in the Setting of Graves’ Disease: Report of a Case and Review of Previously Reported Cases. Case Rep Med. 2016;2016:9653412. doi:10.1155/2016/9653412.
229. Nishio N, Katsura T, Ashida K, et al. Modulation of P-glycoprotein expression in hyperthyroid rat tissues. Drug Metab Dispos. 2005;33:1584-7.
230. Pawlak Cieślik A, Szturmowicz M, Fijałkowska A, еt al. Diagnosis of malignant pericarditis: a single centre experience. Kardiol Pol. 2012;70(11):1147-53. PMID: 23180523.
231. Kotake M, Imai H, Kaira K, et al. Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: a pilot study. Cancer Chemother Pharmacol. 2019;84(3):655-60. doi:10.1007/s00280-019-03897-0.
232. El Haddad D, Iliescu C, Yusuf SW, et al. Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion. J Am Coll Cardiol. 2015;66:1119-28. doi:10.1016/j.jacc.2015.06.1332.
233. Gornik HL, Gerhard-Herman M, Beckman JA. Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion. J Clin Oncol. 2005;23:5211-6. doi:10,1200/JCO.2005.00.745.
234. Labbé C, Tremblay L, Lacasse Y. Pericardiocentesis versus pericardiotomy for malignant pericardial effusion: a retrospective comparison. Curr Oncol. 2015;22(6):412-6. doi:10.3747/co.22.2698.
235. Chang HM, Okwuosa TM, Scarabelli T, et al. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. J Am Coll Cardiol. 2017;70(20):2552-65. doi:10.1016/j.jacc.2017.09.1095.
236. Patel J, Sheppard MN. Pathological study of primary cardiac and pericardial tumours in a specialist UK Centre: surgical and autopsy series. Cardiovasc Pathol. 2010;19:343-52. doi:10.1016/j.carpath.2009.07.005.
237. Rosenbaum AN, Bois MC, Xin Zhang, et al. Primary Malignant Pericardial Mesothelioma: A Clinical Case Series Illustrating the Necessity of a Multidisciplinary Approach. 1 JACC Case Rep. 2019;1(2):202-207. doi:10.1016/j.jaccas.2019.06.012.
238. Karagodin I, Nagle K, Scheidemantle B, et al. Metastatic pericardial mesothelioma: a rare case of constrictive pericarditis. Journal of the American College of Cardiology. 2019;73(9):2640. doi:10.1016/S0735-1097(19)33246-2.
239. Muta H, Sugita Y, Ohshima K, Otsubo H. Primary malignant pericardial sarcomatoid mesothelioma: An autopsy report. Pathol Int. 2017;67(6):311-5. doi:10.1111/pin.12535.
240. Stone CR, Mickle AT, Boyne DJ, et al. Treatment for lymphoma and late cardiovascular disease risk: A systematic review and meta-analysis. Health Sci Rep. 2019;2(10):e135. doi:10.1002/hsr2.135.
241. Maleszewski JJ, Bois MC, Bois JP, et al. Neoplasia and the Heart: Pathological Review of Effects With Clinical and Radiological Correlation. Journal of the American College of Cardiology. 2018;72(2):202-27. doi:10.1016/j.jacc.2018.05.026.
242. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2014;27:911-39. doi:10.1016/j.echo.2014.07.012.
243. Yang X, Liu W, Lyons A, et al. Pericarditis associated with cytarabine therapy for acute myelocytic leukemia: a case report. Eur J Clin Pharmacol. 2018;74(2):181-2. doi:10.1007/s00228-017-2355-7.
244. Wattal S, Rao MS, Chandra GN, et al. Dasatinib Induced Cardiac Tamponade-A Rare Association. J Clin Diagn Res. 2017;11(2):FD03-FD04. doi:10.7860/JCDR/2017/24633.9418.
245. Shaheen S, Mirshahidi H, Nagaraj G, Hsueh CT. Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. Exp Hematol Oncol. 2018;8;7:11. doi:10.1186/s40164-018-0104-y.
246. Malhotra N, Daher G, Hassanieh I, et al. Pericardial effusion with tamponade physiology as an immune-related adverse event secondary to nivolumab. Journal of the American College of Cardiology. 2019;73(9):2613. doi:10.1016/S0735-1097(19)33219-X.
247. Schusler R, Meyerson SL. Pericardial Disease Associated with Malignancy. Curr Cardiol Rep. 2018;20(10):92. doi:10.1007/s11886-018-1040-5.
248. Filopei J, Frishman W. Radiation-induced heart disease. Cardiol Rev. 2012;20:184-8. doi:10.1097/CRD.0b013e3182431c23.
249. Azarbal A, LeWinter MM. Pericardial Effusion. Cardiol Clin. 2017;35(4):515-24. doi:10. 1016/j.ccl.2017.07.005.
250. Besnard A, Raoux F, Khelil N, et al. Current Management of Symptomatic Pericardial Effusions in Cancer Patients. JACC CardioOncology. 2019;1(1):137-140. doi:10.1016/j.jaccao.2019.07.001.
251. Hu ZG, Hu K, Li WX, Zeng FJ. Prognostic factors and nomogram for cancer-specific death in non small cell lung cancer with malignant pericardial effusion. PLoS One. 2019;14(5):e0217007. doi:10.1371/journal.pone.0217007.
252. In-Jeong Cho, Hyuk-Jae Chang, Hyemoon Chung, et al. Prediction of clinical outcome in patients with pericardial effusion and malignancies: stratified by post-pericardiocentesis constrictive physiology. Journal of the American College of Cardiology. 2015;65(10):A1336. doi:10.1016/S0735-1097(15)61336-5.
253. Numico G, Cristofano A, Occelli M, et al. Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion. Medicine (Baltimore). 2016;95(15):e3273. doi:10.1097/MD.0000000000003273.
254. Chen D, Zhang Y, Shi F, et al. Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients. Oncotarget. 2016;7:52436-41. doi:10.18632/oncotarget.9420.
255. Darocha S, Wilk M, Walaszkowska-Czyż A, et al. Determinants of Survival After Emergency Intrapericardial Cisplatin Treatment in Cancer Patients with Recurrent Hemodynamic Instability After Pericardiocentesis. In Vivo. 2018;32(2):373-9. doi:10.21873/invivo.11248.
256. Thill M, Jackisch C, Janni W, Müller V. AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care (Basel). 2019;14(4):247-55. doi:10.1159/000500999.
257. Irazusta FJ, Jiménez-Valero S, Gemma D, et al. CRT-800.48 Percutaneous Balloon Pericardiotomy: Treatment Of Choice In Patients With Advanced Oncological Disease And Severe Pericardial Effusion. JACC: Cardiovascular Interventions. 2017;10(3):S76. doi:10.1016/j.jcin.2016.12.250.
258. Sakanoue I, Hamakawa H, Okubo Y, et al. Efficacy and safety of thoracoscopic pericardial window in patients with pericardial effusions: a single-center case series. J Cardiothorac Surg. 2016;11(1):92. doi:10.1186/s13019-016-0488-x.
259. Celik S, Celik M, Aydemir B, et al. Surgical properties and survival of a pericardial window via left minithoracotomy for benign and malignant pericardial tamponade in cancer patients. World J Surg Oncol. 2012 Jun 28;10:123. doi:10.1186/1477-7819-10-123.
260. Horr S, Mentias A, Klein A. A changing paradigm in the etiology of pericardial effusions? A 12 year study of pericardiocentesis from the cleveland clinic. Journal of the American College of Cardiology. 2016;67(13):1611. doi:10.1016/S0735-1097(16)31612-6.
261. Schwier NC, Coons JC, Rao SK. Pharmacotherapy update of acute idiopathic pericarditis. Pharmacotherapy. 2015;35:99-111.
262. Демин А. А., Дробышева В. П. Болезни перикарда. Российский кардиологический журнал. 2016;(1):90-8. doi:10.15829/1560-4071-2016-1-90-98.
263. Гуревич М. А. Вопросы диагностики, дифференциации и терапии перикардитов. Трудный пациент. 2016;14(4-5):11-6.
264. Темникова Е. А., Кондратьев А. И., Савилова В. В. и др. Трудный диагноз. Острый инфаркт миокарда или миоперикардит? Лечащий врач. 2019;(1):71.
265. Lee LN, Yang PC, Chang DB, et al. Ultrasound guided pericardial drainage and intrapericardial instillation of mitomycin C for malignant pericardial effusion. Thorax. 1994;49:594-5.
266. Martinoni A, Cipolla CM, Cardinale D, et al. Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa. Chest. 2004;126:1412-6.
267. Maher EA, Shepherd FA, Todd TJ. Pericardial sclerosis as the primary management of malignant pericardial effusion and cardiac tamponade. J Thorac Cardiovasc Surg. 1996;112:637-43.
268. Imazio M, Lazaros G, Gattorno M, et al. Anti-interleukin-1 agents for pericarditis: a primer for cardiologists. European Heart Journal. 2021;1-12. doi:10.1093/eurheartj/ehab452.
269. Кlein AL, Imazio M, Brucato A, et al. RHAPSODY: Rationale for and design of pivotal Phase trial to assess efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis. Am Heart J. 2020;228:81-90. doi:10.1016/j.ahj.2020.07.004.
270. Brucato A, Imazio M, Gattorno M, et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence The AIRTRIP Randomized Clinical Trial. JAMA. 2016;316(18):1906-12.
271. Klein AL, Imazio M, Cremer P, et al. Phase 3 trial of Interleukin-1 Trap rilonacept in recurrent pericarditis. N Engl J Med. 2021;384:31-41.
272. Gurevich MA, Mravian SR, Grigor’eva NM. Myopericarditis: clinical picture, diagnosis and treatment. Klinicheskaia Meditsina. 1999;77(7):33-6.
273. Khandaker MH, Schaff HV, Greason KL, et al. Pericardiectomy vs medical management in patients with relapsing pericarditis. Mayo Clinic Proceedings. Elsevier. 2012;87(11):1062-70.
274. Glick Frasiolas JA, Cahoon Jr WD. Intrapericardial triamcinolone administration for autoreactive pericarditis. Annals of Pharmacotherapy. 2010;44(10):1641-6.
275. Титов К. С., Волков С. М. Демидов Л. В. и др. Адаптивная внутриперикардиальная иммунотерапия у больных с метастатическими перикардитами. РМЖ. 2012;1:14.
276. Cherian G. Diagnosis of tuberculous aetiology in pericardial effusions. Postgraduate medical journal. 2004;80(943):262-6.
277. Corey GR, Campbell PT, Van Trigt P, et al. Etiology of large pericardial effusions. The American journal of medicine. 1993;95(2):209-13.
278. Титов К. С. и др. Биотерапия опухолевых перикардитов. Российский биотерапевтический журнал. 2009;8:9-12.
279. Defouilloy C, Meyer G, Slama M, et al. Intrapericardial fibrinolysis: a useful treatment in the management of purulent pericarditis. Intensive care medicine. 1997;23(1):117-8.
280. Thavendrarajah V, Ghia PS, Kozinn W, Little T. Catheter lavage and drainage of pneumococcal pericarditis. Catheterization and cardiovascular diagnosis. 1993;29(4):322-4.